Treatment of Pegylated Interferon-α2a in Chronic Hepatitis B Patients Demonstrating a Spontaneous Decline in HBV DNA after Acute Exacerbation

Abstract

Background

Acute exacerbation (AE) in chronic hepatitis B (CHB) is usually followed by a spontaneous decline in HBV DNA levels. The subsequent treatment is controversial. In this study, we evaluated the efficacy and safety of pegylated interferon-α2a (PEG-IFN-α2a) for such CHB patients.

Methods

A total of 74 hepatitis B e antigen (HBeAg)-positive patients with a spontaneous HBV DNA decline (by >2 log₁₀ IU•ml^-1, compared with baseline levels before antiviral treatment) after AE (alanine aminotransferase [ALT]: 10–30-fold the upper limit of normal [ULN], total bilirubin [TBIL]: 2–20 mg•dl^-1, prothrombin time activity >60%) were included. In total, 22 patients (group A) received PEG-IFN-α2a treatment (180 μg•kg^-1•week^-1, when ALT was <10 ULN and TBIL<2 mg•dl^-1) for 48 weeks, with 48 weeks of treatment-free follow-up. Twenty-one patients (group B) selected continual entecavir therapy. Thirty-one patients (group C, control group) received routine liver-protective drugs.

Results

At week 96, virological response rates were 90.5%, 100% and 48%, and ALT normalization rates were 81%, 95% and 40% for groups A, B and C, respectively. HBeAg seroconversion rates were 71.4%, 45% and 32% in groups A, B and C, respectively. A high hepatitis B surface antigen (HBsAg) loss rate was observed in PEG-IFN-α2a-treated patients, while no entecavir-treated patients achieved HBsAg loss. Group A patients suffered from typical PEG-IFN therapy-related adverse events. No severe adverse event was observed in any groups.

Conclusions

PEG-IFN-α2a is effective and safe for treating CHB patients demonstrating a spontaneous decline in HBV DNA after AE, and yields an increased likelihood of HBsAg loss.

References

Lai

C.L.

, Ratziu

, Yuen

M.F.

, Poynard

Viral hepatitis B.

Lancet 2003; 362: 2089–2094.

Lok

A.S.

Chronic hepatitis B.

N Engl J Med 2002; 346: 1682–1683.

Mahoney

F.J.

Update on diagnosis, management, and prevention of hepatitis B virus infection.

Clin Microbiol Rev 1999; 12: 351–366.

Lee

W.M.

Hepatitis B virus infection.

N Engl J Med 1997; 337: 1733–1745.

Liaw

Y.F.

Hepatitis fares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy.

J Gastroenterol Hepatol 2003; 18: 246–252.

Yuen

M.F.

, Yuan

H.J.

, Hui

C.K.

A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.

Gut 2003; 52: 416–419.

Jing

, Zide

, Yue

, Junqiang

, Liang

, Zhiliang

[The epidemiological features of spontaneous decrease of HBV DNA level in chronic hepatitis B patients].

Chin J Infect Dis 2009; 27: 228–233. Chinese.

Papatheodoridis

G.V.

, Manolakopoulos

, Archimandritis

A.J.

Current treatment indications and strategies in chronic hepatitis B virus infection.

World J Gastroenterol 2008; 14: 6902–6910.

Liaw

Y.F.

, Chu

C.M.

Hepatitis B virus infection.

Lancet 2009; 373: 582–592.

10.

Zoulim

, Perrillo

, Hepatitis

Refections on the current approach to antiviral therapy.

J Hepatol 2008; 48: S2–S19.

11.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B.

Hepatology 2007; 45: 507–539.

12.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B: update 2009.

Hepatology 2009; 50: 661–662.

13.

Janssen

H.L.

, van Zonneveld

, Senturk

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial.

Lancet 2005; 365: 123–129.

14.

Lau

G.K.

, Piratvisuth

, Luo

K.X.

Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

N Engl J Med 2005; 352: 2682–2695.

15.

Marcellin

, Lau

G.K.

, Bonino

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

N Engl J Med 2004; 351: 1206–1217.

16.

European Association for the Study of the Liver.

EASL clinical practice guide-lines: management of chronic hepatitis B.

J Hepatol 2012; 57: 167–185.

17.

European Association for the Study of the Liver.

EASL clinical practice guide-lines: management of chronic hepatitis B.

J Hepatol 2009; 50: 227–242.

18.

Kau

, Vermehren

, Sarrazin

Treatment predictors of a sustained virologic response in hepatitis B and C.

J Hepatol 2008; 49: 634–651.

19.

Akuta

, Tsubota

, Suzuki

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis–an open-cohort study.

J Hepatol 2003; 38: 91–97.

20.

Liaw

Y.F.

, Leung

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Hepatol Int 2008; 2: 263–283.

21.

Chen

C-J

, Yang

H-I

, Jen

C-L

, Su

, lloeje

U.H.

Incidence and determinants of spontaneous decline of HBV DNA to undetectable level in patients with high viral load.

J Hepatol 2010; 52 Suppl 1: S6.

22.

Wong

V.W.

, Wong

G.L.

, Tsang

S.W.

Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.

Antivir Ther 2008; 13: 571–579.

23.

Ganem

, Prince

A.M.

Hepatitis B virus infection natural history and clinical consequences.

N Engl J Med 2004; 350: 1118–1129.

24.

Lee

C.M.

, Ong

G.Y.

, Lu

S.N.

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation.

J Hepatol 2002; 37: 669–674.

25.

Yokosuka

Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.

J Gastroenterol 2004; 39: 813–814.

26.

Nair

, Perrillo

R.P.

Serum alanine aminotransferase fares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?

Hepatology 2001; 34: 1021–1026.

27.

Flink

H.J.

, Sprengers

, Hansen

B.E.

Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferonα-2b therapy.

Gut 2005; 54: 1604–1609.

28.

Chen

C.C.

, Wang

P.C.

, Chang

H.W.

, Chen

C.F.

Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation.

J Viral Hepat 2012; 19: 161–172.

29.

Janssen

H.L.

, van Zonneveld

, Senturk

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

Lancet 2005; 365: 123–129.

30.

Perrillo

R.P.

, Schiff

E.R.

, Davis

G.L.

A randomized, controlled trial of interferon alfa-2B alone and after prednisone withdrawal for the treatment of chronic hepatitis-B.

N Engl J Med 1990; 323: 295–301.

31.

Wong

D.K.H.

, Cheung

A.M.

, O'Rourke

, Naylor

C.D.

, Detsky

A.S.

, Heathcote

Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Ann Intern Med 1993; 119: 312–323.

32.

Lau

G.K.

, Piratvisuth

, Luo

K.X.

Peg-interferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

N Engl J Med 2005; 352: 2682–2695.

33.

Flink

H.J.

, van Zonneveld

, Hansen

B.E.

Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.

Am J Gastroenterol 2006; 101: 297–303.

34.

Buster

E.H.

, Hansen

B.E.

, Lau

G.K.

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.

Gastroenterology 2009; 137: 2002–2009.

35.

Fried

M.W.

, Piratvisuth

, Lau

G.K.

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peg-interferon alfa-2a for HBeAg-positive chronic hepatitis B.

Hepatology 2008; 47: 428–434.

36.

Piratvisuth

, Marcellin

, Popescu

, Kapprell

H.P.

, Rothe

, Lu

Z.M.

Hepatitis B surface antigen: association with sustained response to peg-interferon alfa-2a in hepatitis B e antigen-positive patients.

Hepatol Int 2013; 7: 429–436.

37.

Gane

, Jia

, Han

Neptune study: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peg-interferon alfa-2a in HBeAg-positive patients.

J Hepatol 2011; 54: S31.